Maddy summaryHR 498, the "Do No Harm in Medicaid Act," prohibits federal Medicaid funding for gender transition procedures for individuals under 18 years old. The bill amends the Social Security Act to define "specified gender transition procedures" broadly, including surgeries, hormone treatments, and certain medications, and bans federal Medicaid coverage for these services for minors. Exceptions are made only for medically necessary treatments related to precocious puberty, genetic disorders of sex development, or urgent medical conditions requiring bodily correction (like infections or injuries from prior procedures). This directly affects minors enrolled in Medicaid state plans, as states would no longer receive federal funds for these specific covered services.
Sponsored bills
Maddy summaryThis bill allows groups of small businesses or self-employed individuals to form a single health plan that treats all members as one employer for coverage purposes. It directly affects small business associations and self-employed people who can join such groups to access pooled health coverage, provided they meet specific requirements (e.g., 51+ total employees, 2+ years in existence, no health-based discrimination). Key mechanisms include permitting modified community rating for premiums (based on pooled claims) while prohibiting health status-related discrimination in enrollment, premiums, or pre-existing condition coverage. The plan remains subject to federal ERISA rules, and self-employed members must meet defined criteria to participate as both employers and employees.
Miracle on Ice Congressional Gold Medal Act This act provides for the award of Congressional Gold Medals to the members of the 1980 U.S. Olympic men's ice hockey team in recognition of the team's achievement at the 1980 Winter Olympic Games.
Maddy summaryHR 6643, the American Border Story Memorial Act, authorizes a nonprofit organization ("The American Border Story") to establish a commemorative memorial on federal land in Washington, D.C., to honor U.S. citizens and legal residents who died due to crimes committed by individuals unlawfully present in the U.S. The bill prohibits the use of federal funds for the memorial's creation or maintenance, requiring all costs to be covered by private donations. Any remaining funds after project costs must be deposited into specific federal or National Park Foundation accounts, as outlined in the Commemorative Works Act. This is a procedural memorial bill with no direct policy or regulatory changes.
Maddy summaryThis bill amends the Clean Air Act to clarify when certain plastic conversion facilities are excluded from the definition of "solid waste incineration units." It directly affects companies operating facilities that transform plastic or post-use polymers (via methods like pyrolysis) into usable materials, provided at least 50% of the output by mass is a "product" (e.g., usable substances for sale or manufacturing), not energy or ash. Key mechanisms include adding a specific exclusion for qualifying conversion units (Section 2(A)(iv)) and creating a 180-day petition process for other similar units to seek exclusion (Section 2(B)). The bill defines "product" to exclude electricity, heat, or ash but include materials with commercial applications.
Maddy summaryThis bill amends the Natural Gas Act to give the Federal Energy Regulatory Commission (FERC) exclusive authority to approve U.S. LNG export terminal projects, requiring FERC to deem such exports consistent with the public interest. It directly affects natural gas companies seeking to build or expand export facilities and streamlines FERC's review process by removing prior requirements for interagency coordination. The bill clarifies that FERC's decisions won't override existing sanctions laws, including restrictions on trade with countries designated as state sponsors of terrorism under current law. This change aims to accelerate domestic LNG export projects while maintaining legal safeguards for national security and foreign policy.
Maddy summaryThe Freedom to Heal Act of 2025 creates a new federal registration process for physicians to directly administer Schedule I investigational drugs under the "Right to Try" framework. It requires physicians to apply to the Attorney General with evidence of state compliance, manufacturer agreements, and training, and limits the amount of drugs they may possess based on approved applications. The bill mandates the Attorney General to issue interim rules within 240 days and final rules within two years covering drug delivery, storage, recordkeeping, and registration management. This affects physicians treating eligible patients with Schedule I drugs under federal Right to Try provisions, not the patients themselves.
Maddy summaryHR 3806, the New World Screwworm Preparedness Act of 2025, requires the U.S. Department of Agriculture to conduct a study on the nation's readiness to prevent and respond to New World screwworm (NWS) infestations. The study must assess current threats, sterile insect production capabilities, surveillance systems, emergency response plans, research needs, and international cooperation, with input from livestock producers, wildlife agencies, and scientists. The Secretary of Agriculture must submit a report to Congress within six months detailing findings and recommendations for improving preparedness. This bill directly affects agricultural stakeholders and wildlife management by mandating a review of existing capabilities, not by changing current policy.
Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research. The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)
Maddy summaryThe HUD Transparency Act of 2025 requires the Inspector General of the Department of Housing and Urban Development (HUD) to testify annually before specific congressional committees. Each October 1, the IG must report on six key areas: fraud prevention efforts, audit capabilities, program improvements, efficiency recommendations, resource sufficiency for HUD’s mission, and ongoing oversight activities. This bill directly affects HUD’s Inspector General and Congress, mandating structured, annual accountability reporting. It creates a concrete mechanism for Congress to monitor HUD’s oversight effectiveness without altering HUD’s programs or funding. The law focuses on transparency in existing oversight processes, not new policy changes.